INDIVIDUALIZED MULTIPLE-DAY SIMULATION MODEL OF TYPE 1 DIABETIC PATIENT DECISION-MAKING FOR DEVELOPING, TESTING AND OPTIMIZING INSULIN THERAPIES DRIVEN BY GLUCOSE SENSORS
    262.
    发明申请
    INDIVIDUALIZED MULTIPLE-DAY SIMULATION MODEL OF TYPE 1 DIABETIC PATIENT DECISION-MAKING FOR DEVELOPING, TESTING AND OPTIMIZING INSULIN THERAPIES DRIVEN BY GLUCOSE SENSORS 审中-公开
    葡萄糖传感器驱动的1型糖尿病患者的独立多模式模拟模型,用于开发,测试和优化胰岛素治疗

    公开(公告)号:US20160342754A1

    公开(公告)日:2016-11-24

    申请号:US15158047

    申请日:2016-05-18

    Applicant: DEXCOM, INC.

    Abstract: A mathematical model of type 1 diabetes (T1D) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. insulin dosing) driven by either self-monitoring blood glucose (SMBG) or continuous glucose monitoring (CGM). The decision-making (DM) model can simulate real-life situations and everyday patient behaviors, Accurate submodels of SMBG and CGM measurement errors are incorporated in the comprehensive DM model. The DM model accounts for common errors the patients are used to doing in their diabetes management, such as miscalculations of meal carbohydrate content, early/delayed insulin administrations and missed insulin boluses. The DM model can be used to assess in silico if/when CGM can safely substitute SMBG in T1D management, to develop and test guidelines for CGM driven insulin dosing, to optimize and individualize off-line insulin therapies and to develop and test decision support systems.

    Abstract translation: 1型糖尿病(T1D)患者决策的数学模型可用于在各种受试者(例如胰岛素给药)的驱动下,以数学方式模拟现实的葡萄糖/胰岛素动力学数天 自我监测血糖(SMBG)或连续葡萄糖监测(CGM)。 决策(DM)模型可以模拟现实生活中的情况和日常患者行为,SMBG和CGM测量误差的准确子模型被并入综合DM模型。 DM模型解释了患者在糖尿病管理中常常遇到的错误,例如膳食碳水化合物含量错误计算,胰岛素早期/延迟和胰岛素排泄错误。 如果/当CGM可以安全地替代T1D管理中的SMBG,DM模型可用于评估CGM驱动的胰岛素给药的准则,优化和个性化离线胰岛素治疗,并开发和测试决策支持系统 。

Patent Agency Ranking